Company news

Pacira BioSciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029

May 9, 2024

Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes

May 7, 2024

Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

May 6, 2024

Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program

May 6, 2024

Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024

April 29, 2024

Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

April 1, 2024

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

March 12, 2024

Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference

March 5, 2024

Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results

February 28, 2024

Pacira to Report 2023 Financial Results on Thursday February 29, 2024

February 21, 2024

Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

February 14, 2024

Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.

February 6, 2024

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues

January 3, 2024

Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Pacira Appoints Frank D. Lee as Chief Executive Officer

December 20, 2023

Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

November 9, 2023

Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November

November 6, 2023

Pacira BioSciences Reports Third Quarter 2023 Financial Results

November 1, 2023

Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023

October 25, 2023

Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors

October 9, 2023

American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient Care

October 1, 2023

Pacira BioSciences Announces Leadership Succession Plan

September 25, 2023

Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference

September 5, 2023

Pacira BioSciences Reports Second Quarter 2023 Financial Results

August 1, 2023

Pacira to Report Second Quarter 2023 Financial Results on Wednesday August 2, 2023

July 25, 2023

Pacira BioSciences to Participate in Fireside Chat at the 2023 Jefferies Healthcare Conference

May 30, 2023

Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference

May 8, 2023

Pacira BioSciences Reports First Quarter 2023 Financial Results

May 2, 2023

Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023

April 25, 2023

Pacira BioSciences Partners with The Invited Celebrity Classic – a PGA TOUR Champions Event – to Make iovera° The Official Non-Opioid Pain Management Partner

April 19, 2023

Pacira BioSciences, Inc. Appoints Christopher Young as Chief Manufacturing Officer

April 18, 2023

Pacira BioSciences to Participate in Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference

April 11, 2023

Pacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using Proceeds from New $150 Million 5-Year Term Loan A Facility and Existing Cash Resources

April 2, 2023

Pacira Announces FDA Acceptance of sNDA for Exparel Nerve Blocks to Produce Regional Analgesia in Lower Extremity Procedures

March 28, 2023

Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors

March 21, 2023

Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference

March 7, 2023

Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results

February 27, 2023

LPGA, Pacira BioSciences Partner to Raise Awareness of Non-Opioid Pain Management Solutions

February 22, 2023

Pacira to Report 2022 Financial Results on Tuesday February 28, 2023

February 20, 2023

Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million

January 4, 2023

Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Pacira BioSciences Reports Preliminary Net Product Sales of $57.5 Million for November 2022

December 12, 2022

Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022

November 13, 2022

Pacira BioSciences to Present at Two Healthcare Conferences in November

November 7, 2022

Pacira BioSciences Reports Third Quarter 2022 Financial Results

November 2, 2022

Pacira to Report Third Quarter 2022 Financial Results on Thursday November 3, 2022

October 19, 2022

Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million

October 12, 2022

Sevāredent Sourcing Solutions and Pacira BioSciences Collaborate to Provide Expanded Access to EXPAREL for Patients Undergoing Oral and Maxillofacial Procedures

September 26, 2022

Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

September 20, 2022

Pacira Receives Positive CHMP Opinion for EXPAREL® for the Treatment of Postsurgical Pain in Children Aged 6 or Older

September 19, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 17 decks. Every deck is listed under its year.